Tumor antigen cross-presentation and the dendritic cell: Where it all begins?

Clinical and Developmental Immunology

Volumn 2010, Issue , 2010, Pages

  McDonnell, Alison M ^a   Robinson, Bruce W S ^a,b   Currie, Andrew J ^a,c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b National Centre for Asbestos Related Diseases   (Australia)

^c MURDOCH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CYCLOPHOSPHAMIDE; GLYCOPROTEIN GP 100; HEAT SHOCK PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN; MONOPHENOL MONOOXYGENASE; MUCIN 1; TUMOR ANTIGEN;

ANTIGEN PRESENTING CELL; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEATH; CELL FUNCTION; CELL MIGRATION; CELLULAR DISTRIBUTION; CROSS PRESENTATION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; IMMUNE RESPONSE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL; TUMOR IMMUNITY; TUMOR LOCALIZATION; ANIMAL; ANTIGEN PRESENTATION; ARTICLE; IMMUNOLOGY; MOUSE; TRANSGENIC MOUSE;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; CROSS-PRIMING; DENDRITIC CELLS; MICE; MICE, TRANSGENIC;

EID: 78349245955     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2010/539519     Document Type: Review

References (129)

1. Ochsenbein A. F., Sierro S., Odermatt B., Pericin M., Karrer U., Hermans J., Hemmi S., Hengartner H., Zinkernagel R. M., Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction Nature 2001 411 6841 1058 1064
2. Zinkernagel R. M., On cross-priming of MHC class I-specific CTL: rule or exception? European Journal of Immunology 2002 32 9 2385 2392
3. Boonman Z. F. H. M., Van Mierlo G. J. D., Fransen M. F., Franken K. L. M. C., Offringa R., Melief C. J. M., Jager M. J., Toes R. E. M., Intraocular tumor antigen drains specifically to submandibular lymph nodes, resulting in an abortive cytotoxic T cell reaction Journal of Immunology 2004 172 3 1567 1574
4. Huang A. Y. C., Golumbek P., Ahmadzadeh M., Jaffee E., Pardoll D., Levitsky H., Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens Science 1994 264 5161 961 965 (Pubitemid 24196166)
5. McDonnell A. M., Prosser A. C., van Bruggen I., CD8alpha+ DC are not the sole subset cross-presenting cell-associated tumor antigens from a solid tumor European Journal of Immunology 2010 40 6 1617 1627
6. Nowak A. K., Lake R. A., Marzo A. L., Scott B., Heath W. R., Collins E. J., Frelinger J. A., Robinson B. W. S., Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells Journal of Immunology 2003 170 10 4905 4913
7. Seung S., Urban J. L., Schreiber H., A tumor escape variant that has lost one major histocompatibility complex class I restriction element induces specific CD8+ T cells to an antigen that no longer serves as a target Journal of Experimental Medicine 1993 178 3 933 940
8. Van Mierlo G. J. D., Boonman Z. F. H. M., Dumortier H. M. H., Den Boer A. TH., Fransen M. F., Nouta J., Van Der Voort E. I. H., Offringa R., Toes R. E. M., Melief C. J. M., Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication Journal of Immunology 2004 173 11 6753 6759
9. Cuenca A., Cheng F., Wang H., Brayer J., Horna P., Gu L., Bien H., Borrello I. M., Levitsky H. I., Sotomayor E. M., Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens Cancer Research 2003 63 24 9007 9015
10. Gerner M. Y., Casey K. A., Mescher M. F., Defective MHC class II presentation by dendritic cells limits CD4 T cell help for antitumor CD8 T cell responses Journal of Immunology 2008 181 1 155 164
11. Lyman M. A., Aung S., Biggs J. A., Sherman L. A., A spontaneously arising pancreatic tumor does not promote the differentiation of naive CD8+ T lymphocytes into effector CTL 1 Journal of Immunology 2004 172 11 6558 6567
12. Mapara M. Y., Sykes M., Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance Journal of Clinical Oncology 2004 22 6 1136 1151
13. Staveley-O'Carroll K., Sotomayor E., Montgomery J., Borrello I., Hwang L., Fein S., Pardoll D., Levitsky H., Induction of antigen-specific T cell anergy: an early event in the course of tumor progression Proceedings of the National Academy of Sciences of the United States of America 1998 95 3 1178 1183
14. Dhodapkar M. V., Dhodapkar K. M., Palucka A. K., Interactions of tumor cells with dendritic cells: balancing immunity and tolerance Cell Death and Differentiation 2008 15 1 39 50
15. Melief C. J. M., Cancer immunotherapy by dendritic cells Immunity 2008 29 3 372 383
16. Hargadon K. M., Brinkman C. C., Sheasley-O'Neill S. L., Nichols L. A., Bullock T. N. J., Engelhard V. H., Incomplete differentiation of antigen-specific CD8 T cells in tumor-draining lymph nodes Journal of Immunology 2006 177 9 6081 6090
17. Chaput N., Conforti R., Viaud S., Spatz A., Zitvogel L., The Janus face of dendritic cells in cancer Oncogene 2008 27 45 5920 5931
18. Perrot I., Blanchard D., Freymond N., Isaac S., Guibert B., Pacheco Y., Lebecque S., Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage Journal of Immunology 2007 178 5 2763 2769
19. Troy A., Davidson P., Atkinson C., Hart D., Phenotypic characterisation of the dendritic cell infiltrate in prostate cancer Journal of Urology 1998 160 1 214 219
20. Rosenberg S. A., Restifo N. P., Yang J. C., Morgan R. A., Dudley M. E., Adoptive cell transfer: a clinical path to effective cancer immunotherapy Nature Reviews Cancer 2008 8 4 299 308
21. Swann J. B., Smyth M. J., Immune surveillance of tumors Journal of Clinical Investigation 2007 117 5 1137 1146
22. Bevan M. J., Minor H antigens introduced on H2 different stimulating cells cross react at the cytotoxic T cell level during in vivo priming Journal of Immunology 1976 117 6 2233 2238
23. Bevan M. J., Cross priming for a secondary cytotoxic respsonse to minor H antigens with H 2 congenic cells which do not cross react in the cytotoxic assay Journal of Experimental Medicine 1976 143 5 1283 1288
24. Lin M.-L., Zhan Y., Villadangos J. A., Lew A. M., The cell biology of cross-presentation and the role of dendritic cell subsets Immunology and Cell Biology 2008 86 4 353 362
25. Burgdorf S., Kurts C., Endocytosis mechanisms and the cell biology of antigen presentation Current Opinion in Immunology 2008 20 1 89 95
26. Lin M.-L., Zhan Y., Villadangos J. A., Lew A. M., The cell biology of cross-presentation and the role of dendritic cell subsets Immunology and Cell Biology 2008 86 4 353 362
27. Kang W. D., Choi H. S., Kim S. M., Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer Gynecologic Oncology 2010 116 1 57 60
28. Hildner K., Edelson B. T., Purtha W. E., Diamond M., Matsushita H., Kohyama M., Calderon B., Schraml B. U., Unanue E. R., Diamond M. S., Schreiber R. D., Murphy T. L., Murphy K. M., Batf3 deficiency reveals a critical role for CD8 + dendritic cells in cytotoxic T cell immunity Science 2008 322 5904 1097 1100
29. Heath W. R., Carbone F. R., Dendritic cell subsets in primary and secondary T cell responses at body surfaces Nature Immunology 2009 10 12 1237 1244
30. Villadangos J. A., Schnorrer P., Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo Nature Reviews Immunology 2007 7 7 543 555
31. Belz G. T., Shortman K., Bevan M. J., Heath W. R., CD8 + dendritic cells selectively present MHC class I-restricted noncytolytic viral and intracellular bacterial antigens in vivo Journal of Immunology 2005 175 1 196 200
32. Den Haan J. M. M., Lehar S. M., Bevan M. J., CD8 + but not CD8 - dendritic cells cross-prime cytotoxic T cells in vivo Journal of Experimental Medicine 2000 192 12 1685 1695
33. Pooley J. L., Heath W. R., Shortman K., Cutting edge: intravenous soluble antigen is presented to CD4 T cells by CD8- dendritic cells, but cross-presented to CD8 T cells by CD8+ dendritic cells Journal of Immunology 2001 166 9 5327 5330
34. Shortman K., Heath W. R., The CD8+ dendritic cell subset Immunological Reviews 2010 234 1 18 31
35. Filippi C., Hugues S., Cazareth J., Julia V., Glaichenhaus N., Ugolini S., CD4+ T cell polarization in mice is modulated by strain-specific major histocompatibility complex-independent differences within dendritic cells Journal of Experimental Medicine 2003 198 2 201 209
36. Itano A. A., Jenkins M. K., Antigen presentation to naive CD4 T cells in the lymph node Nature Immunology 2003 4 8 733 739
37. Den Haan J. M. M., Bevan M. J., Constitutive versus activation-dependent cross-presentation of immune complexes by CD8 + and CD8 - dendritic cells in vivo Journal of Experimental Medicine 2002 196 6 817 827
38. Morn G. L., Rueda P., Casal I., Leclerc C., CD8 -CD11b+ dendritic cells present exogenous virus-like particles to CD8+ T cells and subsequently express CD8 -and CD205 molecules Journal of Experimental Medicine 2002 195 10 1233 1245
39. Ruedl C., Storni T., Lechner F., Bchi T., Bachmann M. F., Cross-presentation of virus-like particles by skin-derived CD8- dendritic cells: a dispensable role for TAP European Journal of Immunology 2002 32 3 818 825
40. Backer R., van Leeuwen F., Kraal G., den Haan J. M. M., CD8- dendritic cells preferentially cross-present Saccharomyces cerevisiae antigens European Journal of Immunology 2008 38 2 370 380
41. Ballesteros-Tato A., Leon B., Lund F. E., Temporal changes in dendritic cell subsets, cross-priming and costimulation via CD70 control CD8 + T cell responses to influenza Nature Immunology 2010 11 3 216 224
42. Bedoui S., Whitney P. G., Waithman J., Eidsmo L., Wakim L., Caminschi I., Allan R. S., Wojtasiak M., Shortman K., Carbone F. R., Brooks A. G., Heath W. R., Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells Nature Immunology 2009 10 5 488 495
43. Del Rio M.-L., Rodriguez-Barbosa J.-I., Kremmer E., Frster R., CD103- and CD103+ bronchial lymph node dendritic cells are specialized in presenting and cross-presenting innocuous antigen to CD4+ and CD8+ T cells Journal of Immunology 2007 178 11 6861 6866
44. Zou W., Chen L., Inhibitory B7-family molecules in the tumour microenvironment Nature Reviews Immunology 2008 8 6 467 477
45. Burgdorf S., Kautz A., Bhnert V., Knolle P. A., Kurts C., Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation Science 2007 316 5824 612 616
46. Burgdorf S., Lukacs-Kornek V., Kurts C., The mannose receptor mediates uptake of soluble but not of cell-associated antigen for cross-presentation Journal of Immunology 2006 176 11 6770 6776
47. Castelli C., Rivoltini L., Andreola G., Carrabba M., Renkvist N., Parmiani G., T-cell recognition of melanoma-associated antigens Journal of Cellular Physiology 2000 182 3 323 331
48. Creaney J., Segal A., Sterrett G., Platten M. A., Baker E., Murch A. R., Nowak A. K., Robinson B. W. S., Millward M. J., Overexpression and altered glycosylation of MUC1 in malignant mesothelioma British Journal of Cancer 2008 98 9 1562 1569
49. Malkin A., Kellen J. A., Lickrish G. M., Bush R. S., Carcinoembryonic antigen (CEA) and other tumor markers in ovarian and cervical cancer Cancer 1978 42 3 1452 1456
50. Bachem A., Guttler S., Hartung E., Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells The Journal of Experimental Medicine 2010 207 6 1273 1281
51. Caminschi I., Proietto A. I., Ahmet F., Kitsoulis S., Teh J. S., Lo J. C. Y., Rizzitelli A., Wu L., Vremec D., Van Dommelen S. L. H., Campbell I. K., Maraskovsky E., Braley H., Davey G. M., Mottram P., Van De Velde N., Jensen K., Lew A. M., Wright M. D., Heath W. R., Shortman K., Lahoud M. H., The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement Blood 2008 112 8 3264 3273
52. Galibert L., Diemer G. S., Liu Z., Johnson R. S., Smith J. L., Walzer T., Comeau M. R., Rauch C. T., Wolfson M. F., Sorensen R. A., Van Der Vuurst De Vries A.-R., Branstetter D. G., Koelling R. M., Scholler J., Fanslow W. C., Baum P. R., Derry J. M., Yan W., Nectin-like protein 2 defines a subset of T-cell zone dendritic cells and is a ligand for Class-I-restricted T-cell-associated molecule Journal of Biological Chemistry 2005 280 23 21955 21964
53. Jongbloed S. L., Kassianos A. J., McDonald K. J., Clark G. J., Ju X., Angel C. E., Chen C. -J.J., Dunbar P. R., Wadley R. B., Jeet V., Vulink A. J.E., Hart D. N.J., Radford K. J., Human CD141 + (BDCA-3) + dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens Journal of Experimental Medicine 2010 207 6 1247 1260
54. Poulin L. F., Salio M., Griessinger E., Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells The Journal of Experimental Medicine 2010 207 6 1261 1271
55. Robbins S. H., Walzer T., Dembl D., Thibault C., Defays A., Bessou G., Xu H., Vivier E., Sellars M., Pierre P., Sharp F. R., Chan S., Kastner P., Dalod M., Novel insights into the relationships between dendritic cell subsets in human and mouse revealed by genome-wide expression profiling Genome Biology 2008 9 1, article no. R17
56. Gigante M., Blasi A., Loverre A., Mancini V., Battaglia M., Selvaggi F. P., Maiorano E., Napoli A., Castellano G., Storkus W. J., Gesualdo L., Ranieri E., Dysfunctional DC subsets in RCC patients: ex vivo correction to yield an effective anti-cancer vaccine Molecular Immunology 2009 46 5 893 901
57. Beckebaum S., Zhang X., Chen X., Yu Z., Frilling A., Dworacki G., Grosse-Wilde H., Broelsch C. E., Gerken G., Cicinnati V. R., Increased levels of interleukin-10 in serum from patients with hepatocellular carcinoma correlate with profound numerical deficiencies and immature phenotype of circulating dendritic cell subsets Clinical Cancer Research 2004 10 21 7260 7269
58. Von Garnier C., Filgueira L., Wikstrom M., Smith M., Thomas J. A., Strickland D. H., Holt P. G., Stumbles P. A., Anatomical location determines the distribution and function of dendritic cells and other APCs in the respiratory tract Journal of Immunology 2005 175 3 1609 1618
59. Wikstrom M. E., Stumbles P. A., Mouse respiratory tract dendritic cell subsets and the immunological fate of inhaled antigens Immunology and Cell Biology 2007 85 3 182 188
60. Takenaka S., Safroneeva E., Xing Z., Gauldie J., Dendritic cells derived from murine colonic mucosa have unique functional and phenotypic characteristics Journal of Immunology 2007 178 12 7984 7993
61. Bosma B. M., Metselaar H. J., Mancham S., Boor P. P. C., Kusters J. G., Kazemier G., Tilanus H. W., Kuipers E. J., Kwekkeboom J., Characterization of human liver dendritic cells in liver grafts and perfusates Liver Transplantation 2006 12 3 384 393
62. John R., Nelson P. J., Dendritic cells in the kidney Journal of the American Society of Nephrology 2007 18 10 2628 2635
63. Akbari O., DeKruyff R. H., Umetsu D. T., Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen Nature Immunology 2001 2 8 725 731
64. Belz G. T., Smith C. M., Kleinert L., Reading P., Brooks A., Shortman K., Carbone F. R., Heath W. R., Distinct migrating and nonmigrating dendritic cell population are involved in MHC class I-restricted antigen presentation after lung infection with virus Proceedings of the National Academy of Sciences of the United States of America 2004 101 23 8670 8675
65. Chung Y., Chang J.-H., Kim B.-K., Lee J.-M., Kim H.-Y., Kang C.-Y., Anatomic location defines antigen presentation by dendritic cells to T cells in response to intravenous soluble antigens European Journal of Immunology 2007 37 6 1453 1462
66. Chung Y., Chang J.-H., Kweon M.-N., Rennert P. D., Kang C.-Y., CD8 -11b+ dendritic cells but not CD8 + dendritic cells mediate cross-tolerance toward intestinal antigens Blood 2005 106 1 201 206
67. Sauer K. A., Maxeiner J. H., Karwot R., Scholtes P., Lehr H. A., Birkenbach M., Blumberg R. S., Finotto S., Immunosurveillance of lung melanoma metastasis in EBI-3-deficient mice mediated by CD8+ T cells Journal of Immunology 2008 181 9 6148 6157
68. Wojas K., Tabarkiewicz J., Jankiewicz M., Roliski J., Dendritic cells in peripheral blood of patients with breast and lung cancera pilot study Folia Histochemica et Cytobiologica 2004 42 1 45 48
69. Alvarez D., Vollmann E. H., von Andrian U. H., Mechanisms and consequences of dendritic cell migration Immunity 2008 29 3 325 342
70. Allan R. S., Waithman J., Bedoui S., Jones C. M., Villadangos J. A., Zhan Y., Lew A. M., Shortman K., Heath W. R., Carbone F. R., Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming Immunity 2006 25 1 153 162
71. GeurtsvanKessel C. H., Willart M. A. M., Van Rijt L. S., Muskens F., Kool M., Baas C., Thielemans K., Bennett C., Clausen B. E., Hoogsteden H. C., Osterhaus A. D. M. E., Rimmelzwaan G. F., Lambrecht B. N., Clearance of influenza virus from the lung depends on migratory langerin+CD11b- but not plasmacytoid dendritic cells Journal of Experimental Medicine 2008 205 7 1621 1634
72. Preynat-Seauve O., Schuler P., Contassot E., Beermann F., Huard B., French L. E., Tumor-infiltrating dendritic cells are potent antigen-presenting cells able to activate T cells and mediate tumor rejection Journal of Immunology 2006 176 1 61 67
73. Stoitzner P., Green L. K., Jung J. Y., Price K. M., Ataera H. T., Kivell B., Ronchese F., Inefficient presentation of tumor-derived antigen by tumor-infiltrating dendritic cells Cancer Immunology, Immunotherapy 2008 57 11 1675
74. Vicari A. P., Chiodoni C., Vaure C., At-Yahia S., Dercamp C., Matsos F., Reynard O., Taverne C., Merle P., Colombo M. P., O'Garra A., Trinchieri G., Caux C., Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody Journal of Experimental Medicine 2002 196 4 541 549
75. Pinzon-Charry A., Maxwell T., Lpez J. A., Dendritic cell dysfunction in cancer: a mechanism for immunosuppression Immunology and Cell Biology 2005 83 5 451 461
76. Gerner M. Y., Mescher M. F., Antigen processing and MHC-II presentation by dermal and tumor-infiltrating dendritic cells Journal of Immunology 2009 182 5 2726 2737
77. Ishida T., Oyama T., Carbone D. P., Gabrilovich D. I., Defective function of langerhans cells in tumor-bearing animals is the result of defective maturation from hemopoietic progenitors Journal of Immunology 1998 161 9 4842 4851
78. Lucas A. D., Halliday G. M., Progressor but not regressor skin tumours inhibit Langerhans' cell migration from epidermis to local lymph nodes Immunology 1999 97 1 130 137
79. Carlson G. W., Murray D. R., Lyles R. H., Staley C. A., Hestley A., Cohen C., The amount of metastatic melanoma in a sentinel lymph node: does it have prognostic significance? Annals of Surgical Oncology 2003 10 5 575 581
80. Gobardhan P. D., Elias S. G., Madsen E. V. E., Bongers V., Ruitenberg H. J. M., Perre C. I., Van Dalen T., Prognostic value of micrometastases in sentinel lymph nodes of patients with breast carcinoma: a cohort study Annals of Oncology 2009 20 1 41 48
81. Imoto S., Ochiai A., Okumura C., Wada N., Hasebe T., Impact of isolated tumor cells in sentinel lymph nodes detected by immunohistochemical staining European Journal of Surgical Oncology 2006 32 10 1175 1179
82. Rena O., Carsana L., Cristina S., Papalia E., Massera F., Errico L., Bozzola C., Casadio C., Lymph node isolated tumor cells and micrometastases in pathological stage I non-small cell lung cancer: prognostic significance European Journal of Cardio-Thoracic Surgery 2007 32 6 863 867
83. Scheunemann P., Stoecklein N. H., Hermann K., Rehders A., Eisenberger C. F., Knoefel W. T., Hosch S. B., Occult disseminated tumor cells in lymph nodes of patients with gastric carcinoma. A critical appraisal of assessment and relevance Langenbeck's Archives of Surgery 2009 394 1 105 113
84. Carlson G. W., Murray D. R., Lyles R. H., Staley C. A., Hestley A., Cohen C., The amount of metastatic melanoma in a sentinel lymph node: does it have prognostic significance? Annals of Surgical Oncology 2003 10 5 575 581
85. Johnston F. M., Tan M. C., Tan B. R. Jr., Porembka M. R., Brunt E. M., Linehan D. C., Simon P. O. Jr., Plambeck-Suess S., Eberlein T. J., Hellstrom K. E., Hellstrom I., Hawkins W. G., Goedegebuure P., Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer Clinical Cancer Research 2009 15 21 6511 6518
86. Walz J., Haese A., Scattoni V., Steuber T., Chun F. K. H., Briganti A., Montorsi F., Graefen M., Huland H., Karakiewicz P. I., Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower Cancer 2008 113 10 2695 2703
87. Andr F., Schartz N. E. C., Chaput N., Flament C., Raposo G., Amigorena S., Angevin E., Zitvogel L., Tumor-derived exosomes: a new source of tumor rejection antigens Vaccine 2002 20 4 A28 A31
88. Zeelenberg I. S., Ostrowski M., Krumeich S., Bobrie A., Jancic C., Boissonnas A., Delcayre A., Le Pecq J.-B., Combadire B., Amigorena S., Thry C., Targeting tumor antigens to secreted membrane vesicles in vivo induces efficient antitumor immune responses Cancer Research 2008 68 4 1228 1235
89. Smyth L. A., Harker N., Turnbull W., El-Doueik H., Klavinskis L., Kioussis D., Lombardi G., Lechler R., The relative efficiency of acquisition of MHC:peptide complexes and cross-presentation depends on dendritic cell type Journal of Immunology 2008 181 5 3212 3220
90. Iyoda T., Shimoyama S., Liu K., Omatsu Y., Akiyama Y., Maeda Y., Takahara K., Steinman R. M., Inaba K., The CD8+ dendritic cell subset selectively endocytoses dying cells in culture and in vivo Journal of Experimental Medicine 2002 195 10 1289 1302
91. Kurts C., Miller J. F. A. P., Subramaniam R. M., Carbone F. R., Heath W. R., Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction Journal of Experimental Medicine 1998 188 2 409 414
92. Steinman R. M., Hawiger D., Liu K., Bonifaz L., Bonnyay D., Mahnke K., Iyoda T., Ravetch J., Dhodapkar M., Inaba K., Nussenzweig M., Dendritic cell function in vivo during the steady state: a role in peripheral tolerance Annals of the New York Academy of Sciences 2003 987 15 25
93. Hernndez J., Aung S., Marquardt K., Sherman L. A., Uncoupling of proliferative potential and gain of effector function by CD8+ T cells responding to self-antigens Journal of Experimental Medicine 2002 196 3 323 333
94. Redmond W. L., Sherman L. A., Peripheral tolerance of CD8 T lymphocytes Immunity 2005 22 3 275 284
95. Boise L. H., Minn A. J., Noel P. J., June C. H., Accavitti M. A., Lindsten T., Thompson C. B., CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-x(L) Immunity 1995 3 1 87 98
96. Belkaid Y., Oldenhove G., Tuning microenvironments: induction of regulatory T cells by dendritic cells Immunity 2008 29 3 362 371
97. Munn D. H., Mellor A. L., Indoleamine 2,3-dioxygenase and tumor-induced tolerance Journal of Clinical Investigation 2007 117 5 1147 1154
98. Munn D. H., Sharma M. D., Hou D., Baban B., Lee J. R., Antonia S. J., Messina J. L., Chandler P., Koni P. A., Mellor A. L., Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes Journal of Clinical Investigation 2004 114 2 280 290
99. Sharma M. D., Baban B., Chandler P., Hou D.-Y., Singh N., Yagita H., Azuma M., Blazar B. R., Mellor A. L., Munn D. H., Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase Journal of Clinical Investigation 2007 117 9 2570 2582
100. Broomfield S. A., van der Most R. G., Prosser A. C., Mahendran S., Tovey M. G., Smyth M. J., Robinson B. W., Currie A. J., Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy Journal of Immunology 2009 182 9 5217 5224
101. Jackaman C., Lew A. M., Zhan Y., Allan J. E., Koloska B., Graham P. T., Robinson B. W. S., Nelson D. J., Deliberately provoking local inflammation drives tumors to become their own protective vaccine site International Immunology 2008 20 11 1467 1479
102. Nowak A. K., Robinson B. W.S., Lake R. A., Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors Cancer Research 2003 63 15 4490 4496
103. Stumbles P. A., Himbeck R., Frelinger J. A., Collins E. J., Lake R. A., Robinson B. W. S., Cutting edge: tumor-specific CTL are constitutively cross-armed in draining lymph nodes and transiently disseminate to mediate tumor regression following systemic CD40 activation Journal of Immunology 2004 173 10 5923 5928
104. Currie A. J., Van Der Most R. G., Broomfield S. A., Prosser A. C., Tovey M. G., Robinson B. W. S., Targeting the effector site with IFN- -inducing TLR ligands reactivates tumor-resident CD8 T cell responses to eradicate established solid tumors Journal of Immunology 2008 180 3 1535 1544
105. Stary G., Bangert C., Tauber M., Strohal R., Kopp T., Stingl G., Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells Journal of Experimental Medicine 2007 204 6 1441 1451
106. Currie A. J., Prosser A., McDonnell A., Cleaver A. L., Robinson B. W.S., Freeman G. J., Van Der Most R. G., Dual control of antitumor CD8 T cells through the programmed death-1/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counterregulation Journal of Immunology 2009 183 12 7898 7908
107. Fife B. T., Bluestone J. A., Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways Immunological Reviews 2008 224 1 166 182
108. Keir M. E., Francisco L. M., Sharpe A. H., PD-1 and its ligands in T-cell immunity Current Opinion in Immunology 2007 19 3 309 314
109. Apetoh L., Ghiringhelli F., Tesniere A., Obeid M., Ortiz C., Criollo A., Mignot G., Maiuri M. C., Ullrich E., Saulnier P., Yang H., Amigorena S., Ryffel B., Barrat F. J., Saftig P., Levi F., Lidereau R., Nogues C., Mira J.-P., Chompret A., Joulin V., Clavel-Chapelon F., Bourhis J., Andr F., Delaloge S., Tursz T., Kroemer G., Zitvogel L., Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy Nature Medicine 2007 13 9 1050 1059
110. Casares N., Pequignot M. O., Tesniere A., Ghiringhelli F., Roux S., Chaput N., Schmitt E., Hamai A., Hervas-Stubbs S., Obeid M., Coutant F., Mtivier D., Pichard E., Aucouturier P., Pierron G., Garrido C., Zitvogel L., Kroemer G., Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death Journal of Experimental Medicine 2005 202 12 1691 1701
111. Obeid M., Tesniere A., Ghiringhelli F., Fimia G. M., Apetoh L., Perfettini J.-L., Castedo M., Mignot G., Panaretakis T., Casares N., Mtivier D., Larochette N., Van Endert P., Ciccosanti F., Piacentini M., Zitvogel L., Kroemer G., Calreticulin exposure dictates the immunogenicity of cancer cell death Nature Medicine 2007 13 1 54 61 (Pubitemid 46067386)
112. Suzuki E., Kapoor V., Jassar A. S., Kaiser L. R., Albelda S. M., Gemcitabine selectively eliminates splenic Gr-1+/CD11b + myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity Clinical Cancer Research 2005 11 18 6713 6721
113. Van Cruijsen H., Van Der Veldt A. A. M., Vroling L., Oosterhoff D., Broxterman H. J., Scheper R. J., Giaccone G., Haanen J. B. A. G., Van Den Eertwegh A. J. M., Boven E., Hoekman K., De Gruijl T. D., Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival Clinical Cancer Research 2008 14 18 5884 5892
114. van der Most R. G., Currie A. J., Cleaver A. L., Salmons J., Nowak A. K., Mehendran S., Larma I., Prosser A., Robinson B. W. S., Smyth M. J., Scalzo A. A., Degli-Esposti M. A., Lake R. A., Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth PLoS ONE 2009 4 9
115. van der Most R. G., Currie A. J., Mahendran S., Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy Cancer Immunology, Immunotherapy 2009 58 8 1219 1228
116. Ghiringhelli F., Menard C., Puig P. E., Ladoire S., Roux S., Martin F., Solary E., Le Cesne A., Zitvogel L., Chauffert B., Metronomic cyclophosphamide regimen selectively depletes CD4 +CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients Cancer Immunology, Immunotherapy 2007 56 5 641 648
117. Lutsiak M. E. C., Semnani R. T., De Pascalis R., Kashmiri S. V. S., Schlom J., Sabzevari H., Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide Blood 2005 105 7 2862 2868
118. Vincent J., Mignot G., Chalmin F., Ladoire S., Bruchard M., Chevriaux A., Martin F., Apetoh L., Rb C., Ghiringhelli F., 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity Cancer Research 2010 70 8 3052 3061
119. Aymeric L., Apetoh L., Ghiringhelli F., Tesniere A., Martins I., Kroemer G., Smyth M. J., Zitvogel L., Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity Cancer Research 2010 70 3 855 858
120. Ghiringhelli F., Larmonier N., Schmitt E., Parcellier A., Cathelin D., Garrido C., Chauffert B., Solary E., Bonnotte B., Martin F., CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative European Journal of Immunology 2004 34 2 336 344
121. Zitvogel L., Apetoh L., Ghiringhelli F., Kroemer G., Immunological aspects of cancer chemotherapy Nature Reviews Immunology 2008 8 1 59 73
122. Hu D.-E., Moore A. M., Thomsen L. L., Brindle K. M., Uric acid promotes tumor immune rejection Cancer Research 2004 64 15 5059 5062
123. Shi Y., Evans J. E., Rock K. L., Molecular identification of a danger signal that alerts the immune system to dying cells Nature 2003 425 6957 516 521
124. Nowak A. K., Lake R. A., Marzo A. L., Scott B., Heath W. R., Collins E. J., Frelinger J. A., Robinson B. W. S., Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells Journal of Immunology 2003 170 10 4905 4913
125. Ko H.-J., Kim Y.-J., Kim Y.-S., Chang W.-S., Ko S.-Y., Chang S.-Y., Sakaguchi S., Kang C.-Y., A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model Cancer Research 2007 67 15 7477 7486
126. Sinha P., Clements V. K., Bunt S. K., Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response The Journal of Immunology 2007 179 2 977 983
127. Plate J. M. D., Plate A. E., Shott S., Bograd S., Harris J. E., Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas Cancer Immunology, Immunotherapy 2005 54 9 915 925
128. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y.-J., Pulendran B., Palucka K., Immunobiology of dendritic cells Annual Review of Immunology 2000 18 767 811
129. Gabrilovich D., Mechanisms and functional significance of tumour-induced dendritic-cell defects Nature Reviews Immunology 2004 4 12 941 952